Neue Therapieoptionen mit kontinuierlich gemessenen Glukosedaten – Empfehlungen für die Praxis

Jochen Seufert; Dorothee Deiss; Stefan Gölz; Thomas Haak; Gerhard Klausmann; Jens Kroeger; Ralf Lobmann; Andreas F.H. Pfeiffer; Oliver Schnell; Alexander Seibold; Thorsten Siegmund; Ralph Ziegler

doi:10.1055/a-0978-4537

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2019; 14(05): 388-398
DOI: 10.1055/a-0978-4537

Übersicht

Neue Therapieoptionen mit kontinuierlich gemessenen Glukosedaten – Empfehlungen für die Praxis

Novel Therapeutic Options with Continuous Glucose Monitoring – Practical Recommendations

Authors

Jochen Seufert

¹Klinik für Innere Medizin II, Abteilung Endokrinologie und Diabetologie, Universitätsklinikum Freiburg, Germany
Dorothee Deiss

²Berlin-Mitte, Medicover, Berlin, Germany
Stefan Gölz

³Diabetes Schwerpunktpraxis, Esslingen, Germany
Thomas Haak

⁴Bad Mergentheim, Diabetes-Klinik, Bad Mergentheim, Germany
Gerhard Klausmann

⁵Dres. Klausmann, Gemeinschaftspraxis, Aschaffenburg, Germany
Jens Kroeger

⁶Diabetologie, Zentrum für Diabetologie Hamburg-Bergedorf, Hamburg, Germany
Ralf Lobmann

⁷Klinik für Endokrinologie, Diabetologie und Geriatrie, Klinikum Stuttgart, Krankenhaus Bad Cannstatt, Stuttgart, Germany
Andreas F.H. Pfeiffer

⁸Klinik für Endokrinologie, Stoffwechsel- und Ernährungsmedizin, Charité – Universitätsmedizin Berlin, Germany
Oliver Schnell

⁹Helmholtz Zentrum München, Forschergruppe Diabetes e. V., München-Neuherberg, Germany
Alexander Seibold

¹⁰Abbott GmbH & Co. KG, Wiesbaden, Germany
Thorsten Siegmund

¹¹Diabetes-, Hormon- und Stoffwechselzentrum, Isarklinikum, München, Germany
Ralph Ziegler

¹²Diabetologische Schwerpunktpraxis für Kinder und Jugendliche, Münster, Germany

Abstract

Zusammenfassung

Kontinuierliches Glukosemonitoring (Continuous Glucose Monitoring – CGM) ist heute fest in Konsensusempfehlungen und Leitlinien zur Verbesserung der glykämischen Kontrolle bei Menschen mit insulinpflichtigem Diabetes mellitus verankert. In der täglichen Praxis werden im Besonderen HbA_1c, Glukosevariabilität und Hypoglykämien durch die Nutzung von CGM positiv beeinflusst. Der Stellenwert von CGM bei Therapieentscheidungen wächst und birgt weitere vielfältige Potenziale. Dieser Übersichtsartikel stellt dar, welche Therapieoptionen auf der Basis von CGM-Daten bestehen, wie das ambulante Glukoseprofil und Trendpfeile Therapieentscheidungen beeinflussen können und welche Schulungskonzepte für Patienten angeboten werden. Auch werden zukünftige Felder für die Anwendung von CGM erörtert und diskutiert.

Abstract

Continuous glucose monitoring (CGM) is now firmly anchored in consensus recommendations and guidelines for improving glycaemic control in people with insulin-treated diabetes mellitus. In daily practice, especially HbA_1c, glucose variability and hypoglycaemia are positively affected by the use of CGM. The importance of utilisation of CGM for treatment decisions is growing and holds further broad potential. This review article outlines treatment options based on CGM-derived data, how the ambulatory glucose profile and trend arrows can influence therapy decisions, and what kinds of training programs are offered to patients. Also, future potential areas of use of CGM are outlined and discussed.

Schlüsselwörter

CGM - Flash - Continuous Glucose Monitoring - Flash Glucose Monitoring - Kontinuierliches Glukosemonitoring

Key words

CGM - flash - continuous glucose monitoring - flash glucose monitoring

Full Text

References

Literatur
1 IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: Recommendations for Standard, Comprehensive, and Minimal Care. Diabet Med 2006; 23: 579-593
2 Ceriello A, Colagiuri S. International Diabetes Federation Guideline for Management of Postmeal Glucose: a Review of Recommendations. Diabet Med 2008; 25: 1151-1156
3 American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2018; 41: 1-159
4 Fonseca VA, Grunberger G, Anhalt H. et al. Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract 2016; 22: 1008-1021
5 Grunberger G, Bailey T, Camacho PM. et al. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Glucose Monitoring. Endocr Pract 2015; 21: 522-533
6 Deutsche Diabetes Gesellschaft. S3 – Leitlinie Therapie des Typ-1-Diabetes. 2013, 20.03.2019, https://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/2018/S3-LL-Therapie-Typ-1-Diabetes-Auflage-2-Langfassung-09042018.pdf
7 Deutsche Diabetes Gesellschaft. Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften, S3-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. 2015, 20.03.2019, http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/2016/DM_im_Kinder-_und_Jugendalter-final-2016.pdf
8 Deutsche Diabetes Gesellschaft. S2e-Leitlinie Diabetes und Straßenverkehr. 2017, 20.03.2019, https://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/2017/Leitlinie_S2e_Diabetes_und_Stra%C3%9Fenverkehr_Endfassung.pdf
9 Deutsche Diabetes Gesellschaft. AG Diabetes & Technologie, Stellungnahme der AGDT zum Einsatz von Blutglukosemessungen durch Messungen mit Systemen zum kontinuierlichen real-time Glukosemonitoring (rtCGM) oder CGM mit intermittieredem Scannen (iscCGM). 2016, 20.03.2019, https://www.diabetes-technologie.de/images/pdfs/AGDT_Stellungnahme_Replacement_20160130-L.pdf
10 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Leitliniensynopse für das DMP Diabetes mellitus Typ 1 – Abschlussbericht. 2018, 13.07.2018, https://www.iqwig.de/de/projekte-ergebnisse/projekte/versorgung/v16-02-leitlinienrecherche-zur-aktualisierung-des-dmp-diabetes-mellitus-typ-1.7708.html
11 Deutsche Diabetes Gesellschaft. Arbeitsgemeinschaft Diabetes und Technologie, Aktualisierte Stellungnahme der DDG Arbeitsgemeinschaft Diabetes und Technologie (AGDT) zum Ersatz von Blutglukosemessungen durch Messungen mit Systemen zum kontinuierlichen real-time Glukosemonitoring (rtCGM) oder mit intermittierendem Scannen (iscCGM). 2019, 21.06.2019, https://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Stellungnahmen/2019/Stellungnahme_der_AGDT_2019_5_28_clean.pdf
12 Liebl A, Henrichs HR, Heinemann L. et al. Continuous Glucose Monitoring: Evidence and Consensus Statement for Clinical Use. J Diabetes Sci Technol 2013; 7: 500-519
13 Bailey TS, Grunberger G, Bode BW. et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocr Pract 2016; 22: 231-261
14 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. [D12-01] Kontinuierliche interstitielle Glukosemessung (CGM) mit Real-Time-Messgeräten bei insulinpflichtigem Diabetes mellitus (Abschlussbericht). 2015, 20.11.2018, https://www.iqwig.de/de/projekte-ergebnisse/projekte/nichtmedikamentoese-verfahren/d12-01-kontinuierliche-interstitielle-glukosemessung-cgm-mit-real-time-messgeraten-bei-insulinpflichtigem-diabetes-mellitus.3258.html
15 Lind M, Polonsky W, Hirsch IB. et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA 2017; 317: 379-387
16 Beck RW, Riddlesworth T, Ruedy K. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA 2017; 317: 371-378
17 Battelino T, Conget I, Olsen B. et al. The Use and Efficacy of Continuous Glucose Monitoring in Type 1 Diabetes Treated with Insulin Pump Therapy: a Randomised Controlled Trial. Diabetologia 2012; 55: 3155-3162
18 Tamborlane WV, Beck RW, Bode BW. et al. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. N Engl J Med 2008; 359: 1464-1476
19 van Beers CA, DeVries JH, Kleijer SJ. et al. Continuous Glucose Monitoring for Patients with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia (IN CONTROL): a Randomised, Open-Label, Crossover Trial. Lancet Diabetes Endocrinol 2016; 4: 893-902
20 Little SA, Leelarathna L, Walkinshaw E. et al. Recovery of Hypoglycemia Awareness in Long-Standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-Monitoring (HypoCOMPaSS). Diabetes Care 2014; 37: 2114-2122
21 Battelino T, Phillip M, Bratina N. et al. Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes. Diabetes Care 2011; 34: 795-800
22 Ly TT, Nicholas JA, Retterath A. et al. Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients with Type 1 Diabetes: a Randomized Clinical Trial. JAMA Cardiol 2013; 310: 1240-1247
23 Heinemann L, Freckmann G, Ehrmann D. et al. Real-Time Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Impaired Hypoglycaemia Awareness or Severe Hypoglycaemia Treated with Multiple Daily Insulin Injections (HypoDE): a Multicentre, Randomised Controlled Trial. Lancet 2018; 391: 1367-1377
24 Bolinder J, Antuna R, Geelhoed-Duijvestijn P. et al. Novel Glucose-Sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-Masked, Randomised Controlled Trial. Lancet 2016; 388: 2254-2263
25 Oskarsson P, Antuna R, Geelhoed-Duijvestijn P. et al. Impact of Flash Glucose Monitoring on Hypoglycaemia in Adults with Type 1 Diabetes Managed with Multiple Daily Injection Therapy: a Pre-Specified Subgroup Analysis of the IMPACT Randomised Controlled Trial. Diabetologia 2018; 61: 539-550
26 Seibold A, Welsh Z, Ells S. et al. A Meta-analysis of Real-World Observational Studies on the Impact of Flash Glucose Monitoring on Glycemic Control as Measured by HbA1c. Diabetes 2018; 67: 72-LB
27 Ehrmann D, Heinemann L, Freckmann G. et al. The Effects and Effect Sizes of Real-Time Continuous Glucose Monitoring on Patient-Reported Outcomes: A Secondary Analysis of the HypoDE Study. Diabetes Technol Ther 2019; 21: 86-93
28 Polonsky WH, Hessler D, Ruedy KJ. et al. The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial. Diabetes Care 2017; 40: 736-741
29 Charleer S, Mathieu C, Nobels F. et al. Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. J Clin Endocrinol Metab 2018; 103: 1224-1232
30 Danne T, Nimri R, Battelino T. et al. International Consensus on Use of Continuous Glucose Monitoring. 2017; 40: 1631-1640
31 Haak T, Hanaire H, Ajjan R. et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther 2017; 8: 55-73
32 Beck RW, Riddlesworth TD, Ruedy K. et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med 2017; 167: 365-374
33 Ehrhardt NM, Chellappa M, Walker MS. et al. The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus. J Diabetes Sci Technol 2011; 5: 668-675
34 Fonda SJ, Salkind SJ, Walker MS. et al. Heterogeneity of Responses to Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients with Type 2 Diabetes and Its Implications for Application. Diabetes Care 2013; 36: 786-792
35 Vigersky RA, Fonda SJ, Chellappa M. et al. Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes. Diabetes Care 2012; 35: 32-38
36 Bally L, Thabit H, Hartnell S. et al. Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. N Engl J Med 2018; 379: 547-556
37 Tauschmann M, Thabit H, Bally L. et al. Closed-Loop Insulin Delivery in Suboptimally Controlled Type 1 Diabetes: a Multicentre, 12-Week Randomised Trial. Lancet 2018; 392: 1321-1329
38 The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286
39 UK Prospective Diabetes Study Group. Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ 1998; 317: 703-713
40 Orchard TJ, Nathan DM, Zinman B. et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-Term Mortality. JAMA 2015; 313: 45-53
41 Holman RR, Paul SK, Bethel MA. et al. 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 359: 1577-1589
42 Study G, Gerstein HC, Miller ME. Action to Control Cardiovascular Risk in Diabetes. et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358: 2545-2559
43 Gerstein HC, Miller ME, Genuth S. et al. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. N Engl J Med 2011; 364: 818-828
44 Patel A, MacMahon S, Chalmers J. et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358: 2560-2572
45 McCoy RG, Van Houten HK, Ziegenfuss JY. et al. Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia. Diabetes Care 2012; 35: 1897-1901
46 Bedenis R, Price AH, Robertson CM. et al. Association Between Severe Hypoglycemia, Adverse Macrovascular Events, and Inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care 2014; 37: 3301-3308
47 Khunti K, Davies M, Majeed A. et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care 2015; 38: 316-322
48 Gorst C, Kwok CS, Aslam S. et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care 2015; 38: 2354-2369
49 Smith-Palmer J, Brandle M, Trevisan R. et al. Assessment of the Association Between Glycemic Variability and Diabetes-Related Complications in Type 1 and Type 2 Diabetes. Diabetes Res Clin Pract 2014; 105: 273-284
50 Kilpatrick ES, Rigby AS, Atkin SL. A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes: Data from the Diabetes Control and Complications Trial. Diabetes Care 2008; 31: 2198-2202
51 Selvin E, Rawlings AM, Grams M. et al. Association of 1,5-Anhydroglucitol with Diabetes and Microvascular Conditions. Clin Chem 2014; 60: 1409-1418
52 Zinman B, Marso SP, Poulter NR. et al. Day-to-Day Fasting Glycaemic Variability in DEVOTE: Associations with Severe Hypoglycaemia and Cardiovascular Outcomes (DEVOTE 2). Diabetologia 2018; 61: 48-57
53 Sato H, Hosojima M, Ishikawa T. et al. Glucose Variability Based on Continuous Glucose Monitoring Assessment Is Associated with Postoperative Complications after Cardiovascular Surgery. Ann Thorac Cardiovasc Surg 2017; 23: 239-247
54 Chiasson JL, Josse RG, Gomis R. et al. Acarbose for Prevention of Type 2 Diabetes Mellitus: the STOP-NIDDM Randomised Trial. Lancet 2002; 359: 2072-2077
55 Holman RR, Coleman RL, Chan JCN. et al. Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance (ACE): a Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Diabetes Endocrinol 2017; 5: 877-886
56 The NAVIGATOR Study Group. Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362: 1463-1476
57 Rayman G. Glycaemic Control, Glucose Variability and the Triangle of Diabetes Care. The British Journal of Diabetes 2016; 16: S3-S6
58 Agiostratidou G, Anhalt H, Ball D. et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40: 1622-1630
59 Mazze R, Akkerman B, Mettner J. An Overview of Continuous Glucose Monitoring and the Ambulatory Glucose Profile. Minn Med 2011; 94: 40-44
60 Bergenstal RM, Ahmann AJ, Bailey T. et al. Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile. J Diabetes Sci Technol 2013; 7: 562-578
61 Fonseca V, Grunberger G. Standard Glucose Reporting: Follow-Up to the February 2016 AACE CGM Consensus Conference. Endocr Pract 2017; 23: 629-632
62 Fonseca VA, Grunberger G, Anhalt H. et al. Continuous Glucose Monitoring: A Consensus of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2016; 22: 1008-1021
63 Kröger J, Reichel A, Siegmund T. et al. Praxisbezogene Empfehlungen zum Ambulanten Glukoseprofil. Diabetologie und Stoffwechsel 2018; 13: 174-183
64 Ziegler R, Siegmund T, Von Sengbusch S. et al. Therapieanpassungen mithilfe von Trendpfeilen bei kontinuierlichen Glukosemonitoring (CGM)-Systemen. Diabetologie und Stoffwechsel 2018; 13: 500-509
65 Gehr B, Biermann E, Carstensen S. et al. Spectrum – Schulungs- und Behandlungsprogramm zur kontinuierlichen Glukosemessung (CGM) für Menschen mit Diabetes. Kirchheim Verlag; 2017
66 Kulzer B, Hermanns N, Schnipfer M. et al. flash – Schulungs- und Behandlungsprogramm für Menschen, die Flash Glucose Monitoring benutzen. Kirchheim Verlag; 2017
67 Hermanns N, Ehrmann D, Schipfer M. et al. The Impact of a Structured Education and Treatment Programme (FLASH) for People with Diabetes Using a Flash Sensor-Based Glucose Monitoring System: Results of a Randomized Controlled Trial. Diabetes Res Clin Pract 2019; 150: 111-121
68 Nationale Versorgungsleitlinie. Diabetes: Strukturierte Schulungsprogramme. 2012, 21.01.2019, https://www.leitlinien.de/mdb/downloads/nvl/diabetes-mellitus/dm-schulungsprogramme-1aufl-vers4-lang.pdf
69 Davies MJ, DʼAlessio DA, Fradkin J. et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-2701
70 Carlson AL, Mullen DM, Bergenstal RM. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther 2017; 19: S4-S11
71 Sands AT, Zambrowicz BP, Rosenstock J. et al. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care 2015; 38: 1181-1188
72 Argento NB, Nakamura K. Glycemic Effects of SGLT-2 Inhibitor Canagliflozin in Type 1 Diabetes Patients using the Dexcom G4 Platinum CGM. Endocr Pract 2016; 22: 315-322
73 Nishimura R, Tanaka Y, Koiwai K. et al. Effect of Empagliflozin Monotherapy on Postprandial Glucose and 24-Hour Glucose Variability in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, Double-Blind, Placebo-Controlled, 4-Week Study. Cardiovasc Diabetol 2015; 14: 11
74 King AB, Philis-Tsimikas A, Kilpatrick ES. et al. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technol Ther 2017; 19: 255-264
75 Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Kontinuierliche interstitielle Glukosemessung mit Real-Time-Messgeräten (rtCGM) zur Therapiesteuerung bei Patientinnen und Patienten mit insulinpflichtigem Diabetes mellitus. 2016, 20.03.2019, https://www.g-ba.de/downloads/39-261-2623/2016-06-16_MVV-RL_rtCGM_BAnz.pdf
76 Kröger J, Reichel A, Siegmund T. et al. AGP-Fibel Das Ambulante Glukoseprofil strukturiert auswerten. Mainz: Kirchheim Verlag; 2018